A gene that helps direct the brain's cleanup cells appears to play a central role in Alzheimer's disease, according to new research from UVA Health led by John Lukens, PhD. The gene, CASS4, had already been identified as an Alzheimer's risk factor in numerous studies, but its function was unclear. Lukens and his team found that CASS4 helps guide microglia, the immune cells that clear debris from the brain.
When the gene did not work properly, the microglia lost much of their ability to respond to harmful amyloid-beta plaques. They were also far less able to contain and compact the plaque material, which allowed the plaques to grow faster and spread more aggressively. In lab mice, faulty versions of the gene impaired the microglia, caused amyloid-beta to build up, harmed nerve cells called neurons, and led to cognitive decline.
The findings matter because they shift how researchers understand this genetic risk factor. Lukens said many in the field had assumed CASS4 worked mainly in neurons, but the work shows it acts predominantly through the immune system. First author Addie Walsh, a UVA physiology graduate student, said the study offers new insight into how this understudied risk gene functions in the brain.
The researchers suggest that defective CASS4 activity might one day serve as an early biomarker for Alzheimer's, and that drugs boosting its function could help treat the disease. They also report that the loss of CASS4 set off a cascade of changes in gene activity that may contribute to other neurodegenerative diseases, and the team is now exploring those links. The results come from lab mice and cell studies published in the Journal of Experimental Medicine, so translating them into therapies for people will require substantial further work.